Nektar Therapeutics at Goldman Sachs Healthcare Conference Transcript
Welcome, everyone, to the afternoon start for the 44th Annual Goldman Sachs Healthcare Conference. My name is Chris Shibutani, member of the Biopharma Equity Research team. We are very pleased to have Nektar Therapeutics join us once again. On the dice with me are some veterans of the industry, of the company. Jonathan Zalevsky, also known as JZ, Chief Research and Development Officer; and Jen Ruddock, Chief Business Officer.
Thank you both for joining us.
Thank you.
You guys have been really a part of so many aspects of the journey for the company. We're at an interesting intersection right now. A lot of changes going over the past 6 months, and probably changes that are not necessarily understood or recognized or appreciated as much. And I always
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
